Literature DB >> 26392979

Timing of antiretroviral therapy and effects on tuberculosis treatment outcomes in HIV-co-infected patients in Malawi.

H S Kanyerere1, J Mpunga1, H Tweya2, M Edginton3, A D Harries4, S G Hinderaker5, F Chimbwandira6, A Gonani7, K Mbendera1.   

Abstract

SETTING: Queen Elizabeth Central Hospital, Blantyre, Malawi.
OBJECTIVES: To determine 1) the proportion of human immunodeficiency virus (HIV) infected tuberculosis (TB) patients started on antiretroviral therapy (ART), 2) the timing of ART and 3) the effect of the timing on TB treatment outcomes.
DESIGN: A retrospective record review of HIV-infected TB patients registered from January to December 2009.
RESULTS: A total of 3376 TB patients were registered, of whom 2665 (79%) were HIV-tested and 2042 (77%) were HIV-infected. A total of 1190 HIV-infected TB patients who were not on ART at the time of starting TB treatment were studied. Of 688 (58%) who started ART, 61% started therapy within 2 months of anti-tuberculosis treatment and 39% started later (≥2 months). Treatment success for patients with TB who started ART within 2 months was higher than for those starting ART later (RR 1.6, 95%CI 1.4-1.8), and death rates were lower (RR 0.25, 95%CI 0.19-0.35).
CONCLUSION: Under routine programme conditions in Malawi, a higher proportion of HIV-infected TB patients who started ART did so within 2 months of starting TB treatment, and early ART intervention was associated with better treatment outcomes. This confirms recommendations that co-infected TB patients should start ART early.

Entities:  

Keywords:  Malawi; operational research; timing; tuberculosis

Year:  2012        PMID: 26392979      PMCID: PMC4463069          DOI: 10.5588/pha.12.0029

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  9 in total

Review 1.  Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis.

Authors:  Anthony D Harries; Edwin Libamba; Erik J Schouten; Andrina Mwansambo; Felix M Salaniponi; Rex Mpazanje
Journal:  BMJ       Date:  2004-11-13

2.  Scaling up antiretroviral treatment in resource-poor settings.

Authors:  Anthony D Harries; Erik J Schouten; Edwin Libamba
Journal:  Lancet       Date:  2006-06-03       Impact factor: 79.321

3.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

4.  Integration of antiretroviral therapy with tuberculosis treatment.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew L Gray; Tanuja Gengiah; Santhanalakshmi Gengiah; Anushka Naidoo; Niraksha Jithoo; Gonasagrie Nair; Wafaa M El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

5.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Authors:  Diane V Havlir; Michelle A Kendall; Prudence Ive; Johnstone Kumwenda; Susan Swindells; Sarojini S Qasba; Anne F Luetkemeyer; Evelyn Hogg; James F Rooney; Xingye Wu; Mina C Hosseinipour; Umesh Lalloo; Valdilea G Veloso; Fatuma F Some; N Kumarasamy; Nesri Padayatchi; Breno R Santos; Stewart Reid; James Hakim; Lerato Mohapi; Peter Mugyenyi; Jorge Sanchez; Javier R Lama; Jean W Pape; Alejandro Sanchez; Aida Asmelash; Evans Moko; Fred Sawe; Janet Andersen; Ian Sanne
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

6.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Authors:  François-Xavier Blanc; Thim Sok; Didier Laureillard; Laurence Borand; Claire Rekacewicz; Eric Nerrienet; Yoann Madec; Olivier Marcy; Sarin Chan; Narom Prak; Chindamony Kim; Khemarin Kim Lak; Chanroeurn Hak; Bunnet Dim; Chhun Im Sin; Sath Sun; Bertrand Guillard; Borann Sar; Sirenda Vong; Marcelo Fernandez; Lawrence Fox; Jean-François Delfraissy; Anne E Goldfeld
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

7.  Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi.

Authors:  A D Harries; D S Nyangulu; C Kang'ombe; D Ndalama; J R Glynn; H Banda; J J Wirima; F M Salaniponi; G Liomba; D Maher; P Nunn
Journal:  Trans R Soc Trop Med Hyg       Date:  1998 May-Jun       Impact factor: 2.184

8.  Antiretroviral treatment uptake and attrition among HIV-positive patients with tuberculosis in Kibera, Kenya.

Authors:  K Tayler-Smith; R Zachariah; M Manzi; W Kizito; A Vandenbulcke; J Sitienei; J Chakaya; A D Harries
Journal:  Trop Med Int Health       Date:  2011-08-11       Impact factor: 2.622

9.  Reasons for accepting or refusing HIV services among tuberculosis patients at a TB-HIV integration clinic in Malawi.

Authors:  M Kumwenda; S Tom; A K Chan; E Mwinjiwa; S Sodhi; M Joshua; M van Lettow
Journal:  Int J Tuberc Lung Dis       Date:  2011-12       Impact factor: 2.373

  9 in total
  3 in total

1.  Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts.

Authors:  William Worodria; Victor Ssempijja; Coleen Hanrahan; Richard Ssegonja; Abdallah Muhofwa; Doreen Mazapkwe; Harriet Mayanja-Kizza; Steven J Reynolds; Robert Colebunders; Yukari C Manabe
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

2.  High uptake of antiretroviral therapy among HIV-positive TB patients receiving co-located services in Swaziland.

Authors:  Ishani Pathmanathan; Munyaradzi Pasipamire; Sherri Pals; E Kainne Dokubo; Peter Preko; Trong Ao; Sikhathele Mazibuko; Janet Ongole; Themba Dhlamini; Samson Haumba
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

3.  Tuberculosis treatment outcomes among prisoners and general population in Zomba, Malawi.

Authors:  Victor Singano; Esther Kip; Wilson Ching'ani; Lawrence Chiwaula
Journal:  BMC Public Health       Date:  2020-05-15       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.